Publications (12) Jose Maria Moraleda Jimenez publications

filter_list Cancer Research

2021

  1. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma

    Blood, Vol. 137, Núm. 1, pp. 49-60

2020

  1. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792

  2. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma

    Blood Advances, Vol. 4, Núm. 10, pp. 2163-2171

2019

  1. Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma

    American Journal of Hematology, Vol. 94, Núm. 8, pp. 853-861

2017

  1. Glioblastoma progression is assisted by induction of immunosuppressive function of pericytes through interaction with tumor cells

    Oncotarget, Vol. 8, Núm. 40, pp. 68614-68626

2015

  1. IL-4 up-regulates miR-21 and the miRNAs hosted in the CLCN5 gene in chronic lymphocytic leukemia

    PLoS ONE, Vol. 10, Núm. 4

2014

  1. The Gene Expression Response of Chronic Lymphocytic Leukemia Cells to IL-4 Is Specific, Depends on ZAP-70 Status and Is Differentially Affected by an NFkB Inhibitor

    PLoS ONE, Vol. 9, Núm. 10

2012

  1. Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series

    Leukemia and Lymphoma, Vol. 53, Núm. 5, pp. 812-819

2011

  1. Immunophenotype of acute myeloid leukemia with NPM mutations: Prognostic impact of the leukemic compartment size

    Leukemia Research, Vol. 35, Núm. 2, pp. 163-168

2003

  1. Genetic polymorphisms of platelet adhesive molecules: Association with breast cancer risk and clinical presentation

    Breast Cancer Research and Treatment, Vol. 80, Núm. 2, pp. 145-154

1998

  1. Bone marrow steady-state CD34+/CD71- cell content is a predictive value of rG-CSF-mobilized CD34+ cells

    Bone Marrow Transplantation, Vol. 21, Núm. 10, pp. 983-985

1997

  1. Prospective randomized study comparing the efficacy of bioequivalent doses of glycosylated and nonglycosylated rG-CSF for mobilizing peripheral blood progenitor cells

    British Journal of Haematology, Vol. 96, Núm. 2, pp. 418-420